Literature DB >> 24107760

SSRI versus bupropion effects on symptom clusters in suicidal depression: post hoc analysis of a randomized clinical trial.

Michael F Grunebaum1, John G Keilp, Steven P Ellis, Katherin Sudol, Neal Bauer, Ainsley K Burke, Maria A Oquendo, J John Mann.   

Abstract

OBJECTIVE: Identifying the depression symptoms most closely associated with suicidal thoughts and which medications provide the fastest depression relief may help suicide prevention.
METHOD: Post hoc analysis of data from a randomized, double-blind, 8-week clinical trial of the selective serotonin reuptake inhibitor paroxetine controlled release (n = 36) versus the norepinephrine-dopamine reuptake inhibitor bupropion extended release (n = 38) was conducted in patients with DSM-IV major depressive disorder and past suicide attempt or current suicidal thoughts. Treatment effects on Hamilton Depression Rating Scale (HDRS) and Beck Depression Inventory symptom clusters were compared. We hypothesized that paroxetine would demonstrate a superior effect on nonsuicidal, affective/cognitive depression symptom clusters that our prior work found to be associated with suicidal thoughts and attempts. Data were collected from February 2005 to January 2010.
RESULTS: There was a treatment main effect on HDRS psychic depression (depressed mood, guilt, retardation, helpless, hopeless, worthless) (estimate = -2.2; 95% CI, -3.2 to -1.1; t67.16 = -4.01; P < .001), one of the clusters most strongly correlated to suicidal ideation. The net drug effect demonstrated that mean psychic depression score was 2.2 points lower after 1 week of paroxetine compared to bupropion treatment. The significance level of this effect was P < .001 at weeks 1 and 2, P = .012 at week 3 and P = .051 at week 4. Results for other depression scale factors were nonsignificant (P > .05).
CONCLUSIONS: The results require replication but suggest a pathway by which selective serotonin reuptake inhibitor treatment may exert a stronger effect compared with norepinephrine-dopamine reuptake inhibitor treatment on reduction of suicidal thoughts during initial weeks of pharmacotherapy in these higher risk patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00429169. © Copyright 2013 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24107760      PMCID: PMC4313534          DOI: 10.4088/JCP.12m08000

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  47 in total

1.  Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey.

Authors:  R C Kessler; G Borges; E E Walters
Journal:  Arch Gen Psychiatry       Date:  1999-07

2.  Suicidal ideation and the subjective aspects of depression.

Authors:  John G Keilp; Michael F Grunebaum; Marianne Gorlyn; Simone LeBlanc; Ainsley K Burke; Hanga Galfalvy; Maria A Oquendo; J John Mann
Journal:  J Affect Disord       Date:  2012-03-09       Impact factor: 4.839

Review 3.  Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry.

Authors:  Ralitza Gueorguieva; John H Krystal
Journal:  Arch Gen Psychiatry       Date:  2004-03

4.  Establishing priorities for reducing suicide and its antecedents in the United States.

Authors:  Kerry L Knox; Eric D Caine
Journal:  Am J Public Health       Date:  2005-09-29       Impact factor: 9.308

5.  Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients.

Authors:  J J Mann; K M Malone
Journal:  Biol Psychiatry       Date:  1997-01-15       Impact factor: 13.382

6.  Symptom components of standard depression scales and past suicidal behavior.

Authors:  Michael F Grunebaum; John Keilp; Shuhua Li; Steven P Ellis; Ainsley K Burke; Maria A Oquendo; J John Mann
Journal:  J Affect Disord       Date:  2005-07       Impact factor: 4.839

7.  Neuroanatomic correlates of psychopathologic components of major depressive disorder.

Authors:  Matthew S Milak; Ramin V Parsey; John Keilp; Maria A Oquendo; Kevin M Malone; J John Mann
Journal:  Arch Gen Psychiatry       Date:  2005-04

8.  Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression.

Authors:  Michael F Grunebaum; Steven P Ellis; Naihua Duan; Ainsley K Burke; Maria A Oquendo; J John Mann
Journal:  Neuropsychopharmacology       Date:  2011-10-12       Impact factor: 7.853

9.  Exactly what does the Hamilton Depression Rating Scale measure?

Authors:  R D Gibbons; D C Clark; D J Kupfer
Journal:  J Psychiatr Res       Date:  1993 Jul-Sep       Impact factor: 4.791

Review 10.  Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

Authors:  George I Papakostas; Maurizio Fava
Journal:  Eur Neuropsychopharmacol       Date:  2008-09-26       Impact factor: 4.600

View more
  7 in total

1.  Comparative effectiveness of dual-action versus single-action antidepressants for the treatment of depression in people living with HIV/AIDS.

Authors:  Jon C Mills; Jeffrey S Harman; Robert L Cook; Nicole M Marlow; Christopher A Harle; R Paul Duncan; Angela M Bengtson; Brian W Pence
Journal:  J Affect Disord       Date:  2017-03-19       Impact factor: 4.839

2.  Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales.

Authors:  Elizabeth D Ballard; Julia S Yarrington; Cristan A Farmer; Marc S Lener; Bashkim Kadriu; Níall Lally; Deonte Williams; Rodrigo Machado-Vieira; Mark J Niciu; Lawrence Park; Carlos A Zarate
Journal:  J Affect Disord       Date:  2018-02-05       Impact factor: 4.839

3.  Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs. bupropion.

Authors:  Marianne Gorlyn; John Keilp; Ainsley Burke; Maria Oquendo; J John Mann; Michael Grunebaum
Journal:  Psychiatry Res       Date:  2014-12-13       Impact factor: 3.222

Review 4.  Pharmacological interventions for self-harm in adults.

Authors:  Katrina G Witt; Sarah E Hetrick; Gowri Rajaram; Philip Hazell; Tatiana L Taylor Salisbury; Ellen Townsend; Keith Hawton
Journal:  Cochrane Database Syst Rev       Date:  2021-01-10

5.  Future disposition and suicidal ideation: mediation by depressive symptom clusters.

Authors:  Elizabeth D Ballard; Amee B Patel; Martha Ward; Dorian A Lamis
Journal:  J Affect Disord       Date:  2014-08-27       Impact factor: 4.839

6.  Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression.

Authors:  Annabella Hochschild; John G Keilp; Sean P Madden; Ainsley K Burke; J John Mann; Michael F Grunebaum
Journal:  J Affect Disord       Date:  2021-12-22       Impact factor: 4.839

Review 7.  Augmentation with antidepressants in schizophrenia treatment: benefit or risk.

Authors:  Ye-Meng Mao; Ming-Dao Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-16       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.